Add to ORKGcardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309. Question In patients with type 2 diabetes mellitus (DM), how do rosiglita-zone and pioglitazone compare for cardiovascular (CV) outcomes and mortality? Review scope Included studies compared rosiglitazone with pioglitazone in patients with type 2 DM. Outcomes were myocardial infarction (MI), congestive heart failure, and overall mortality. Review method
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
Diabetes mellitus is associated with a number of serious microvascular and macrovascularcomplication...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
OBJECTIVE: To compare the risk of acute myocardial infarction, heart failure, and death in patients ...
BackgroundStudies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (CVD...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
Objective To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglita...
BACKGROUND: Rosiglitazone has several properties that may affect progression of atherosclerosis. The...
Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment...
Anthony H BarnettUniversity of Birmingham and Heart of England National Health Service Foundation Tr...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
mortality compared with other oral diabetes drugs or placebo in type 2 diabetes Selvin E, Bolen S, Y...
The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes ...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
Diabetes mellitus is associated with a number of serious microvascular and macrovascularcomplication...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
OBJECTIVE: To compare the risk of acute myocardial infarction, heart failure, and death in patients ...
BackgroundStudies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (CVD...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
Objective To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglita...
BACKGROUND: Rosiglitazone has several properties that may affect progression of atherosclerosis. The...
Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment...
Anthony H BarnettUniversity of Birmingham and Heart of England National Health Service Foundation Tr...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
mortality compared with other oral diabetes drugs or placebo in type 2 diabetes Selvin E, Bolen S, Y...
The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes ...
Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (C...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...